Recent News

• 06.01.2026 - Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
• 06.01.2026 - Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026
• 05.19.2026 - Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
• 05.19.2026 - Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
• 05.14.2026 - Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
• 05.14.2026 - Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
• 04.30.2026 - ARS - Annual Report to Security Holders

Recent Filings

• 05.29.2026 - 8-K Current report
• 05.29.2026 - EX-99.1 EX-99.1
• 05.19.2026 - 8-K Current report
• 05.19.2026 - EX-99.1 EX-99.1
• 05.15.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.14.2026 - 8-K Current report
• 05.14.2026 - EX-99.1 EX-99.1
• 05.14.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.30.2026 - ARS Annual Report to Security Holders